A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT01626885
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 125
- Registration Number
- NCT01625897
Safety and Efficacy of MP-214 in Patients With Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 512
- Registration Number
- NCT01625000
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
Phase 3
Completed
- Conditions
- Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
- Interventions
- Drug: Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 31
- Registration Number
- NCT01596335
- Locations
- 🇯🇵
Investigational site, Tokai, Japan
Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT01585155
- Locations
- 🇯🇵
Investigational site, Tohoku, Japan
Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT01580670
- Locations
- 🇯🇵
Investigational site, Tohoku, Japan
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Phase 3
Completed
- Conditions
- Behcet SyndromeNeuro-Behcet's DiseaseBehcet's Disease
- Interventions
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT01532570
- Locations
- 🇯🇵
Investigational site, Tohoku, Japan
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: TA-7284 LowDrug: TA-7284 High
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT01512849
- Locations
- 🇯🇵
Reserch site, Kanto, Japan
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
Phase 3
Completed
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 137
- Registration Number
- NCT01492686
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
Phase 3
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT01468584
- Locations
- 🇯🇵
Toranomon Hospital, Minato-ku, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath